Equities analysts expect that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will announce earnings of $0.25 per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. The lowest EPS estimate is $0.23 and the highest is $0.27. Sucampo Pharmaceuticals posted earnings of $0.28 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 10.7%. The firm is scheduled to announce its next earnings results on Wednesday, November 8th.

On average, analysts expect that Sucampo Pharmaceuticals will report full-year earnings of $1.01 per share for the current financial year, with EPS estimates ranging from $0.98 to $1.04. For the next fiscal year, analysts forecast that the business will report earnings of $1.06 per share, with EPS estimates ranging from $0.98 to $1.14. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company had revenue of $59.90 million during the quarter, compared to the consensus estimate of $56.44 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The company’s revenue was up 15.3% compared to the same quarter last year.

SCMP has been the topic of a number of research reports. ValuEngine raised shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Maxim Group set a $23.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. TheStreet lowered shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Finally, Roth Capital set a $30.00 price objective on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $17.29.

In other news, insider Jones W. Bryan purchased 4,700 shares of the company’s stock in a transaction on Friday, August 4th. The shares were purchased at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the transaction, the insider now owns 4,700 shares of the company’s stock, valued at approximately $49,820. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $12.00, for a total transaction of $12,000,000.00. The disclosure for this sale can be found here. Corporate insiders own 4.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SCMP. Great West Life Assurance Co. Can raised its position in Sucampo Pharmaceuticals by 900.8% during the first quarter. Great West Life Assurance Co. Can now owns 35,778 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 32,203 shares in the last quarter. Bank of New York Mellon Corp raised its position in Sucampo Pharmaceuticals by 107.3% during the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after acquiring an additional 190,292 shares in the last quarter. Comerica Bank bought a new stake in Sucampo Pharmaceuticals during the first quarter worth $275,000. Karp Capital Management Corp bought a new stake in Sucampo Pharmaceuticals during the first quarter worth $119,000. Finally, Texas Permanent School Fund bought a new stake in Sucampo Pharmaceuticals during the first quarter worth $197,000. 55.46% of the stock is currently owned by hedge funds and other institutional investors.

Sucampo Pharmaceuticals (NASDAQ SCMP) traded up 2.50% during midday trading on Tuesday, reaching $10.25. 92,690 shares of the company’s stock were exchanged. The stock’s market cap is $474.83 million. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $17.55. The firm’s 50-day moving average is $11.61 and its 200 day moving average is $10.71.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPS” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/10/17/zacks-brokerages-anticipate-sucampo-pharmaceuticals-inc-scmp-to-post-0-25-eps.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.